Fundraising Fox

Branch Therapeutics

Houston, US · Founded 2024 · Delaware corporation

branch-tx.com

Branch Therapeutics develops first-in-class, orally available dual-kinase inhibitors designed to modulate WNT/β-catenin and PI3Kα signaling to target cancer stem cells and treatment resistance in solid tumors. The company pairs its therapies with a precision biomarker strategy aimed at safer, longer-lasting responses to cancer treatment.

BiotechHealthtech

Founders & leadership

Branch Therapeutics was founded in 2024 by Curtis Thorne.

CT
Curtis ThorneCEO and Director
CH
Christopher HulmeNamed on SEC filing

Board

SB
Sourav BanerjeeBoard director

Reported raises · per SEC filings

Form D private placements

$4M disclosed across 1 round · 2025

$4MraisedMay 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sourav BanerjeeDirector
  • Curtis ThorneExecutive Officer, Director
  • Christopher HulmeDirector
Offering amount
$4M
Amount sold
$4M
First sale
Apr 2025
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Branch Therapeutics do?
Branch Therapeutics develops first-in-class, orally available dual-kinase inhibitors designed to modulate WNT/β-catenin and PI3Kα signaling to target cancer stem cells and treatment resistance in solid tumors. The company pairs its therapies with a precision biomarker strategy aimed at safer, longer-lasting responses to cancer treatment.
Who founded Branch Therapeutics?
Branch Therapeutics was founded by Curtis Thorne in 2024.
How much funding has Branch Therapeutics raised?
Branch Therapeutics has disclosed $4M raised across 1 round.
Where is Branch Therapeutics headquartered?
Branch Therapeutics is headquartered in Houston, US.